Sorafenib in Advanced Hepatocellular Carcinoma
In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than f...
Publications
View AllImproved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La ...
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who h...
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previo...
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
The addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, ...
Affiliated Researchers
Institution Info
- Type
- healthcare
- Country
- FR
- Publications
- 5
- Citations
- 31,849
External Links
Identifiers
- ROR
- https://ror.org/021959v84